Pharmacokinetics of Antibiotics in Patients Undergoing Renal Replacement Therapies
ConditionRenal Replacement Therapy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCleveland Clinic Abu Dhabi
About this trial
The study is aiming to describe the pharmacokinetic and pharmacodynamic profile of intravenous meropenem, ertapenem, cefepime, colistin, Ceftazidime/Avibactam , Ceftolozane/Tazobactam , and piperacillin/tazobactam in the plasma and determine how much is removed by Renal Replacement Therapies to ensure adequate dosing
Eligibility criteria
Qualifiers
Adults > 18 year old
Prescribed meropenem, ertapenem, cefepime, colistin, Ceftazidime/Avibactam , Ceftolozane/Tazobactam , or piperacillin/tazobactam for treatment of infection as part of standard medical care
Administered meropenem, ertapenem, cefepime, colistin, Ceftazidime/Avibactam , Ceftolozane/Tazobactam ,or piperacillin/tazobactam while on renal replacement therapy (IHD or CRRT) or renal replacement therapy started while on any of these antibiotics
Patients with hemoglobin > 70 g/L without blood transfusion in the past 24 hours
Disqualifiers
Less than 18 years of age
Pregnant females
Body mass index < 18 or > 35 kg/m2
Presence of anemia (defined as hemoglobin < 70 g/L), thrombocytopenia, or leukopenia as defined by hematocrit, platelet, or white blood cell count < 75% of the lower limit of normal
Trial design
Treatments tested in this trial
- Blood collection
Treatment groups
No treatment groups listed
Sponsors and collaborators
Cleveland Clinic Abu Dhabi
Lead sponsor
University of the Sciences in Philadelphia
Collaborator
Source ClinicalTrials.gov